

References to Part 3: [Brain Dopamine – Clock Interactions Regulate Cardiometabolic Health In T2D](#)

Published Jan. 5, 2021

[OBJ]

1. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. *Circulation*. 2000;101(14):1634-7.
2. Lambert GW, Straznicki NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. *Pharmacol Ther*. 2010;126(2):159-72.
3. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. *Nutr Metab Cardiovasc Dis*. 2007;17(6):473-81.
4. Wulsin LR, Horn PS, Perry JL, Massaro JM, D'Agostino RB. Autonomic Imbalance as a Predictor of Metabolic Risks, Cardiovascular Disease, Diabetes, and Mortality. *J Clin Endocrinol Metab*. 2015;100(6):2443-8.
5. Thorp AA, Schlaich MP. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. *J Diabetes Res*. 2015;2015:341583.
6. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987-1998. *Circulation*. 2003;107(17):2190-5.
7. Egan BM. Insulin resistance and the sympathetic nervous system. *Curr Hypertens Rep*. 2003;5(3):247-54.
8. Tentolouris N, Argyrakopoulou G, Katsilambros N. Perturbed autonomic nervous system function in metabolic syndrome. *Neuromolecular Med*. 2008;10(3):169-78.
9. Wang W, Mu L, Su T, Ye L, Jiang Y, Jiang L, et al. Plasma Metanephrines Are Associated With Glucose Metabolism in Patients With Essential Hypertension. *Medicine (Baltimore)*. 2015;94(37):e1496.
10. Svensson MK, Lindmark S, Wiklund U, Rask P, Karlsson M, Myrin J, et al. Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity? *Cardiovasc Diabetol*. 2016;15:91.
11. Saito I, Maruyama K, Eguchi E, Kato T, Kawamura R, Takata Y, et al. Low Heart Rate Variability and Sympathetic Dominance Modifies the Association Between Insulin Resistance and Metabolic Syndrome-The Toon Health Study. *Circ J*. 2017;81(10):1447-53.

12. Peltonen GL, Scalzo RL, Schweder MM, Larson DG, Luckasen GJ, Irwin D, et al. Sympathetic inhibition attenuates hypoxia induced insulin resistance in healthy adult humans. *J Physiol.* 2012;590(11):2801-9.
13. Indumathy J, Pal GK, Pal P, Ananthanarayanan PH, Parija SC, Balachander J, et al. Decreased baroreflex sensitivity is linked to sympathovagal imbalance, body fat mass and altered cardiometabolic profile in pre-obesity and obesity. *Metabolism.* 2015;64(12):1704-14.
14. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. *Nat Rev Cancer.* 2015;15(9):563-72.
15. Conde SV, Ribeiro MJ, Melo BF, Guarino MP, Sacramento J.F. Insulin resistance: a new consequence of altered carotid body chemoreflex? *J Physiol.* 2017;595(1):31-41.
16. Kalsbeek A, Palm IF, La Fleur SE, Scheer FA, Perreau-Lenz S, Ruiter M, et al. SCN outputs and the hypothalamic balance of life. *J Biol Rhythms.* 2006;21(6):458-69.
17. Buijs RM, Chun SJ, Nijima A, Romijn HJ, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. *J Comp Neurol.* 2001;431(4):405-23.
18. Buijs RM, la Fleur SE, Wortel J, Van Heyningen C, Zuiddam L, Mettenleiter TC, et al. The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. *J Comp Neurol.* 2003;464(1):36-48.
19. Kalsbeek A, La Fleur S, Van Heijningen C, Buijs RM. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. *J Neurosci.* 2004;24(35):7604-13.
20. Scheer FA, Kalsbeek A, Buijs RM. Cardiovascular control by the suprachiasmatic nucleus: neural and neuroendocrine mechanisms in human and rat. *Biol Chem.* 2003;384(5):697-709.
21. Warren WS, Champney TH, Cassone VM. The suprachiasmatic nucleus controls the circadian rhythm of heart rate via the sympathetic nervous system. *Physiol Behav.* 1994;55(6):1091-9.
22. Ruiter M, Buijs RM, Kalsbeek A. Hormones and the autonomic nervous system are involved in suprachiasmatic nucleus modulation of glucose homeostasis. *Curr Diabetes Rev.* 2006;2(2):213-26.
23. Bartness TJ, Song CK, Demas GE. SCN efferents to peripheral tissues: implications for biological rhythms. *J Biol Rhythms.* 2001;16(3):196-204.
24. Purkayastha S, Zhang H, Zhang G, Ahmed Z, Wang Y, Cai D. Neural dysregulation of peripheral insulin action and blood pressure by brain endoplasmic reticulum stress. *Proc Natl Acad Sci U S A.* 2011;108(7):2939-44.
25. Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. *Expert Review of Endocrinology and Metabolism.* 2016;11(2):113-48.
26. Chamarthi B, Vinik A, Ezrokhi M, Cincotta AH. Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus. *Endocrinol Diabetes Metab.* 2020;3(1):e00101.

27. Alghasham A, Rasheed N. Stress-mediated modulations in dopaminergic system and their subsequent impact on behavioral and oxidative alterations: an update. *Pharm Biol.* 2014;52(3):368-77.
28. Davis JF, Tracy AL, Schurdak JD, Tschop MH, Lipton JW, Clegg DJ, et al. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. *Behav Neurosci.* 2008;122(6):1257-63.
29. Geiger BM, Haburcak M, Avena NM, Moyer MC, Hoebel BG, Pothos EN. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. *Neuroscience.* 2009;159(4):1193-9.
30. Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J, et al. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. *J Neurosci.* 2012;32(19):6711-7.
31. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, et al. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. *Neuroimage.* 2008;42(4):1537-43.
32. Luo S, Zhang Y, Ezrokhi M, Li Y, Tsai TH, Cincotta AH. Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet. *J Neuroendocrinol.* 2018;30(1).
33. Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. *Diabetol Metab Syndr.* 2014;6:104.
34. Stoelzel CR, Zhang Y, Cincotta AH. Circadian-timed dopamine agonist treatment reverses high-fat diet-induced diabetogenic shift in ventromedial hypothalamic glucose sensing. *Endocrinol Diabetes Metab.* 2020;3(3):e00139.
35. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. *J Clin Invest.* 1980;65(3):717-21.
36. Lembo G, Capaldo B, Rendina V, Iaccarino G, Napoli R, Guida R, et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. *Am J Physiol.* 1994;266(2 Pt 1):E242-7.
37. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. *Hypertension.* 1993;21(5):618-23.
38. Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S, Andersson O. The hemodynamic link between insulin resistance and hypertension. *J Hypertens.* 1991;9(11):983-6.
39. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. *J Clin Invest.* 1990;85(6):1844-52.
40. Cao W, Shi M, Wu L, Li J, Yang Z, Liu Y, et al. Adipocytes initiate an adipose-cerebral-peripheral sympathetic reflex to induce insulin resistance during high-fat feeding. *Clin Sci (Lond).* 2019;133(17):1883-99.
41. Shimazu T. Central nervous system regulation of liver and adipose tissue metabolism. *Diabetologia.* 1981;20(Suppl 1):343-56.

42. Moore MC, Coate KC, Winnick JJ, An Z, Cherrington AD. Regulation of hepatic glucose uptake and storage in vivo. *Adv Nutr.* 2012;3(3):286-94.
43. Dicostanzo CA, Dardevet DP, Neal DW, Lautz M, Allen E, Snead W, et al. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. *Am J Physiol Endocrinol Metab.* 2006;290(1):E9-E16.
44. Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. *Diabetes Metab Rev.* 1987;3(1):185-206.
45. van den Hoek AM, van Heijningen C, Schroder-van der Elst JP, Ouwens DM, Havekes LM, Romijn JA, et al. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. *Diabetes.* 2008;57(9):2304-10.
46. Shimazu T. Reciprocal innervation of the liver: its significance in metabolic control. *Adv Metab Disord.* 1983;10:355-84.
47. Kraft G, Vrba A, Scott M, Allen E, Edgerton DS, Williams PE, et al. Sympathetic Denervation of the Common Hepatic Artery Lessens Glucose Intolerance in the fat- and Fructose-Fed Dog. *Diabetes.* 2019;68(6):1143-55.
48. Rojas JM, Bruinstroop E, Printz RL, Alijagic-Boers A, Foppen E, Turney MK, et al. Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation. *Mol Metab.* 2015;4(3):210-21.
49. Bruinstroop E, Pei L, Ackermans MT, Foppen E, Borgers AJ, Kwakkel J, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. *Diabetes.* 2012;61(5):1043-50.
50. Geerling JJ, Boon MR, Kooijman S, Parlevliet ET, Havekes LM, Romijn JA, et al. Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. *J Lipid Res.* 2014;55(2):180-9.
51. Hurr C, Simonyan H, Morgan DA, Rahmouni K, Young CN. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. *J Physiol.* 2019;597(17):4565-80.
52. Sabath E, Baez-Ruiz A, Buijs RM. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. *Obes Rev.* 2015;16(10):871-82.
53. Bruinstroop E, Fliers E, Kalsbeek A. Restoring the autonomic balance to reduce liver steatosis. *J Physiol.* 2019;597(18):4683-4.
54. Goodus MT, McTigue DM. Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? *Exp Neurol.* 2020;325:113160.
55. Mesarwi OA, Loomba R, Malhotra A. Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. *Am J Respir Crit Care Med.* 2019;199(7):830-41.
56. Huan H.B., Wen XD, Chen XJ, Wu L, Wu LL, Zhang L, et al. Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells. *Brain Behav Immun.* 2017;59:118-34.

57. Steffens AB, Scheurink AJ, Luiten PG, Bohus B. Hypothalamic food intake regulating areas are involved in the homeostasis of blood glucose and plasma FFA levels. *Physiol Behav.* 1988;44(4-5):581-9.
58. McCarty MF. Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. *Med Hypotheses.* 2004;62(5):830-8.
59. Lopes HF, Correa-Giannella ML, Consolim-Colombo FM, Egan BM. Visceral adiposity syndrome. *Diabetol Metab Syndr.* 2016;8:40.
60. Boden G. Obesity and free fatty acids. *Endocrinol Metab Clin North Am.* 2008;37(3):635-46, viii-ix.
61. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. *Clin Biochem.* 2009;42(13-14):1331-46.
62. Wang YY, Lin SY, Chuang YH, Chen CJ, Tung KC, Sheu WH. Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model. *Am J Physiol Endocrinol Metab.* 2011;300(1):E155-63.
63. Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetnansky R, Zukowska Z. Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. *Ann N Y Acad Sci.* 2008;1148:232-7.
64. Saxton SN, Withers SB, Heagerty AM. Emerging Roles of Sympathetic Nerves and Inflammation in Perivascular Adipose Tissue. *Cardiovasc Drugs Ther.* 2019;33(2):245-59.
65. Ferreira JA, Bissell BD. Misdirected Sympathy: The Role of Sympatholysis in Sepsis and Septic Shock. *J Intensive Care Med.* 2018;33(2):74-86.
66. Liao YT, Wang SM, Wang JR, Yu CK, Liu CC. Norepinephrine and Epinephrine Enhanced the Infectivity of Enterovirus 71. *PLoS One.* 2015;10(8):e0135154.
67. Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature.* 2018;564(7735):273-7.
68. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. *Arthritis Res Ther.* 2014;16(6):504.
69. Abboud FM, Singh MV. Autonomic regulation of the immune system in cardiovascular diseases. *Adv Physiol Educ.* 2017;41(4):578-93.
70. Abboud FM, Harwani SC, Chappleau M.W. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. *Hypertension.* 2012;59(4):755-62.
71. Winklewski PJ, Radkowski M, Demkow U. Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke. *J Neuroinflammation.* 2014;11:213.
72. S.R. RI. Adrenaline fuels a cytokine storm during immunotherapy. *Nature.* 2018;564(7735):194-6.
73. Bellinger DL, Lorton D. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)? *Int J Mol Sci.* 2018;19(4).

74. Ahmari N, Santisteban MM, Miller DR, Geis NM, Larkin R, Redler T, et al. Elevated bone marrow sympathetic drive precedes systemic inflammation in angiotensin II hypertension. *Am J Physiol Heart Circ Physiol*. 2019;317(2):H279-H89.
75. Fonkoue IT, Le NA, Kankam ML, DaCosta D, Jones TN, Marvar PJ, et al. Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure. *Physiol Rep*. 2019;7(7):e14057.
76. Yasunari K, Matsui T, Maeda K, Nakamura M, Watanabe T, Kiriike N. Anxiety-induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension. *Am J Hypertens*. 2006;19(6):573-8.
77. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, et al. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. *Nat Commun*. 2013;4:1403.
78. Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. *Breast Cancer Res Treat*. 2011;125(2):351-62.
79. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of N.K. cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. *Neuroimmunomodulation*. 2000;8(3):154-64.
80. Schuller HM, Cole B. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. *Carcinogenesis*. 1989;10(9):1753-5.
81. Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway. *Hepatogastroenterology*. 2012;59(115):889-93.
82. Lackovicova L, Banovska L, Bundzikova J, Janega P, Bizik J, Kiss A, et al. Chemical sympathectomy suppresses fibrosarcoma development and improves survival of tumor-bearing rats. *Neoplasma*. 2011;58(5):424-9.
83. Horvathova L, Padova A, Tillinger A, Osacka J, Bizik J, Mravec B. Sympathectomy reduces tumor weight and affects expression of tumor-related genes in melanoma tissue in the mouse. *Stress*. 2016;19(5):528-34.
84. Zhi X, Li B, Li Z, Zhang J, Yu J, Zhang L, et al. Adrenergic modulation of AMPK-dependent autophagy by chronic stress enhances cell proliferation and survival in gastric cancer. *Int J Oncol*. 2019;54(5):1625-38.
85. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. *Brain Behav Immun*. 2009;23(2):267-75.
86. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. *Int J Cancer*. 2011;128(10):2306-16.
87. Le CP, Nowell CJ, Kim-Fuchs C, Botteri E, Hiller JG, Ismail H, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. *Nat Commun*. 2016;7:10634.

88. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Res.* 2006;66(21):10357-64.
89. Sood AK, Bhatti R, Kamat AA, Landen CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. *Clin Cancer Res.* 2006;12(2):369-75.
90. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer Res.* 2010;70(18):7042-52.
91. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. *Int J Cancer.* 2006;118(11):2744-9.
92. Bleeker T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. *Circ Res.* 2004;94(1):37-45.
93. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. *J Am Coll Cardiol.* 2002;39(4):683-8.
94. Panico K, Abrahao MV, Trentin-Sonoda M, Muzi-Filho H, Vieyra A, Carneiro-Ramos MS. Cardiac Inflammation after Ischemia-Reperfusion of the Kidney: Role of the Sympathetic Nervous System and the Renin-Angiotensin System. *Cell Physiol Biochem.* 2019;53(4):587-605.
95. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. *Eur J Endocrinol.* 2000;142(4):315-23.
96. Hu A, Jiao X, Gao E, Koch WJ, Sharifi-Azad S, Grunwald Z, et al. Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. *J Pharmacol Exp Ther.* 2006;318(2):469-75.
97. de Lima-Seolin BG, Nemec-Bakk A, Forsyth H, Kirk S, da Rosa Araujo AS, Schenkel PC, et al. Bucindolol Modulates Cardiac Remodeling by Attenuating Oxidative Stress in H9c2 Cardiac Cells Exposed to Norepinephrine. *Oxid Med Cell Longev.* 2019;2019:6325424.
98. Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. *Rev Cardiovasc Med.* 2003;4 Suppl 6:S50-7.
99. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. *Cardiovasc Res.* 2001;50(2):409-16.
100. Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, et al. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. *Int J Cardiol.* 2009;135(3):302-7.
101. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. *Acta Physiol Scand.* 2003;177(3):275-84.

102. Leimbach WN, Jr., Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. *Circulation*. 1986;73(5):913-9.
103. Seravalle G, Grassi G. Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. *High Blood Press Cardiovasc Prev*. 2016;23(3):175-9.
104. DiBona G.F. Sympathetic nervous system and the kidney in hypertension. *Curr Opin Nephrol Hypertens*. 2002;11(2):197-200.
105. Fisher JP, Young CN, Fadel PJ. Central sympathetic overactivity: maladies and mechanisms. *Auton Neurosci*. 2009;148(1-2):5-15.
106. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. *Physiology (Bethesda)*. 2007;22:310-9.
107. Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. *Med Clin North Am*. 2017;101(1):129-37.
108. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. *Curr Opin Nephrol Hypertens*. 2012;21(1):46-51.
109. Saliba LJ, Maffett S. Hypertensive Heart Disease and Obesity: A Review. *Heart Fail Clin*. 2019;15(4):509-17.
110. Converse RL, Jr., Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med*. 1992;327(27):1912-8.
111. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. *Hypertension*. 2011;57(4):846-51.
112. Kaur J, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. *Int J Mol Sci*. 2017;18(8).
113. Mangoni AA, Mircoli L, Giannattasio C, Mancina G, Ferrari AU. Effect of sympathectomy on mechanical properties of common carotid and femoral arteries. *Hypertension*. 1997;30(5):1085-8.
114. Pal GK, Adithan C, Ananthanarayanan PH, Pal P, Nanda N, Durgadevi T, et al. Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics. *PLoS One*. 2013;8(11):e78072.
115. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma Z.J., et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. *Diabetes Care*. 2010;33(7):1503-8.
116. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. *J Am Heart Assoc*. 2012;1(5):e002279.

117. Chamarthi B, Gaziano JM, Blonde L, Vinik A, Scranton RE, Ezrokhi M, et al. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. *J Diabetes Res*. 2015;2015:157698.
118. Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. *Postgrad Med*. 2016;128(8):761-9.
119. Quarti Trevano F, Seravalle G, Macchiarulo M, Villa P, Valena C, Dell'Oro R, et al. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. *J Hypertens*. 2017;35(8):1685-90.
120. Tadic M, Cuspidi C, Grassi G. Heart rate as a predictor of cardiovascular risk. *Eur J Clin Invest*. 2018;48(3).
121. Grassi G, Seravalle G, Mancia G. Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. *Eur J Clin Invest*. 2015;45(12):1367-75.
122. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. *J Hypertens*. 2007;25(5):909-20.
123. Facchini FS, Stoohs RA, Reaven G.M. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. *Am J Hypertens*. 1996;9(10 Pt 1):1013-7.
124. Bemelmans RH, Wassink AM, van der Graaf Y, Nathoe HM, Vernooij JW, Spiering W, et al. Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases. *Eur J Endocrinol*. 2012;166(4):717-25.
125. Aune D, B OH, Vatten LJ. Resting heart rate and the risk of type 2 diabetes: A systematic review and dose--response meta-analysis of cohort studies. *Nutr Metab Cardiovasc Dis*. 2015;25(6):526-34.
126. Chamarthi B CE, Adams J, Alatrach M, Agyin C, Triplitt C, Ezrokhi M, Luo S, Duvallet E, Cincotta AH, DeFronzo R. Bromocriptine-QR (BQR) therapy reduces elevated sympathetic nervous system activity (SNSA) and oxidative stress (O.S.) in type 2 diabetes (T2D) subjects whose dysglycemia is poorly controlled on GLP-1 receptor agonist (GLP-1RA). *Diabetes*. 2019;68:1166-P.